Skip to main content
Watch Insiders
ACADHealthcare

Acadia Pharmaceuticals Inc (ACAD) Insider Trading

In the last 90 days, 1 Acadia Pharmaceuticals Inc (ACAD) insider reported no open-market purchases and 1 sale totaling $587,241. Source: SEC Form 4 filings.

SEC-reported filing activity is provided for research purposes and is not investment advice.

90-day C-suite buyers
0
90-day purchase value
$0.00
Corporate buyers
0
Latest transaction
Aug 6, 2026

Executive filings

Open-market transaction history

Purchase and sale summaries are ordered by the latest reported transaction date.

Open-market insider purchase and sale transactions
DateInsider nameRoleTypeSharesPriceTotal value
Aug 6, 2026Mark C. SchneyerEVP, CHIEF FINANCIAL OFFICERSale20,141$29.16$587,241
Jul 30, 2026Elizabeth H.Z. ThompsonEVP, Head of Research & DevSale16,558$26.13$432,662
Jun 26, 2026James KiharaPRINCIPAL ACCOUNTING OFFICERSale11,421$26.08$297,912
May 26, 2026James KiharaPRINCIPAL ACCOUNTING OFFICERSale5,401$21.18$114,393
May 4, 2026Mark C. SchneyerEVP, CHIEF FINANCIAL OFFICERSale3,506$21.79$76,396
May 4, 2026James KiharaPRINCIPAL ACCOUNTING OFFICERSale1,332$21.79$29,024

Common questions

ACAD insider trading FAQ

Are ACAD insiders buying or selling?
Over the last 90 days, ACAD insiders were net sellers, reporting $0.00 of open-market purchases and $587,241 of sales.
When was the last ACAD insider purchase?
No open-market insider purchase of Acadia Pharmaceuticals Inc stock was reported in the last 90 days.
Where does ACAD insider trading data come from?
Watch Insiders reads the SEC Form 4 filings that Acadia Pharmaceuticals Inc officers, directors, and 10% owners submit to EDGAR, and refreshes this page daily.